Minerva Neurosciences Inc (NERV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has a cash flow conversion efficiency ratio of 0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($-34.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Minerva Neurosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Minerva Neurosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Minerva Neurosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Minerva Neurosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Minerva Neurosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dare Bioscience Inc
NASDAQ:DARE
|
0.508x |
|
Korea Bio-Gen Co.Ltd
KQ:318000
|
0.040x |
|
Lithium Energy Ltd
AU:LEL
|
-0.041x |
|
Carmit
TA:CRMT
|
0.031x |
|
Gurktaler AG ST
VI:GAGS
|
-0.006x |
|
Daesung Eltec Co. Ltd
KQ:025440
|
0.061x |
|
India Globalization Capital Inc
NYSE MKT:IGC
|
-0.258x |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
0.025x |
Annual Cash Flow Conversion Efficiency for Minerva Neurosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Minerva Neurosciences Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Minerva Neurosciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-25.69 Million | $-19.55 Million | 0.761x | +46.46% |
| 2023-12-31 | $-28.46 Million | $-14.78 Million | 0.520x | -57.79% |
| 2022-12-31 | $-20.02 Million | $-24.65 Million | 1.231x | +139.90% |
| 2021-12-31 | $7.98 Million | $-24.60 Million | -3.085x | -380.29% |
| 2020-12-31 | $52.66 Million | $-33.82 Million | -0.642x | +58.92% |
| 2019-12-31 | $27.78 Million | $-43.43 Million | -1.563x | -236.48% |
| 2018-12-31 | $90.26 Million | $-41.94 Million | -0.465x | -2077.04% |
| 2017-12-31 | $131.60 Million | $3.09 Million | 0.024x | +109.70% |
| 2016-12-31 | $105.98 Million | $-25.69 Million | -0.242x | +44.75% |
| 2015-12-31 | $55.32 Million | $-24.27 Million | -0.439x | +37.17% |
| 2014-12-31 | $51.50 Million | $-35.96 Million | -0.698x | -552.28% |
| 2013-12-31 | $20.18 Million | $-2.16 Million | -0.107x | +99.78% |
| 2012-12-31 | $19.02K | $-908.54K | -47.770x | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more